181 related articles for article (PubMed ID: 34128734)
1. Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation.
Brayden DJ; Maher S
Expert Opin Drug Deliv; 2021 Oct; 18(10):1501-1512. PubMed ID: 34128734
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals.
Kim JC; Park EJ; Na DH
Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559036
[TBL] [Abstract][Full Text] [Related]
3. Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs.
Daniel CP; Wagner MJ; Borne GE; Plaisance CJ; Ahmadzadeh S; Aquino A; Shekoohi S; Kaye AM; Cornett EM; Kaye AD
Pathophysiology; 2023 Sep; 30(3):377-388. PubMed ID: 37755395
[TBL] [Abstract][Full Text] [Related]
4. Update on the use of oral octreotide therapy for acromegaly.
Schilbach K; Schopohl J
Expert Rev Endocrinol Metab; 2016 Jul; 11(4):349-355. PubMed ID: 30058923
[TBL] [Abstract][Full Text] [Related]
5. New medical therapies on the horizon: oral octreotide.
Biermasz NR
Pituitary; 2017 Feb; 20(1):149-153. PubMed ID: 28091879
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly.
Uygur MM; Villanova M; Frara S; Giustina A
touchREV Endocrinol; 2024 Apr; 20(1):37-42. PubMed ID: 38812667
[TBL] [Abstract][Full Text] [Related]
7. Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo.
Thanou M; Verhoef JC; Marbach P; Junginger HE
J Pharm Sci; 2000 Jul; 89(7):951-7. PubMed ID: 10861597
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
Fleseriu M; Dreval A; Bondar I; Vagapova G; Macut D; Pokramovich YG; Molitch ME; Leonova N; Raverot G; Grineva E; Poteshkin YE; Gilgun-Sherki Y; Ludlam WH; Patou G; Haviv A; Gordon MB; Biermasz NR; Melmed S; Strasburger CJ
Lancet Diabetes Endocrinol; 2022 Feb; 10(2):102-111. PubMed ID: 34953531
[TBL] [Abstract][Full Text] [Related]
9. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study.
Pavel M; Borson-Chazot F; Cailleux A; Hörsch D; Lahner H; Pivonello R; Tauchmanova L; Darstein C; Olsson H; Tiberg F; Ferone D
Cancer Chemother Pharmacol; 2019 Feb; 83(2):375-385. PubMed ID: 30535537
[TBL] [Abstract][Full Text] [Related]
10. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C
Twarog C; Fattah S; Heade J; Maher S; Fattal E; Brayden DJ
Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30781867
[TBL] [Abstract][Full Text] [Related]
11. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
McKeage K; Cheer S; Wagstaff AJ
Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
[TBL] [Abstract][Full Text] [Related]
12. Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs.
Asano D; Takakusa H; Nakai D
Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258058
[TBL] [Abstract][Full Text] [Related]
13. Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice.
Maggio ET; Grasso P
Regul Pept; 2011 Apr; 167(2-3):233-8. PubMed ID: 21329733
[TBL] [Abstract][Full Text] [Related]
14. Intestinal permeation enhancers to improve oral bioavailability of macromolecules: reasons for low efficacy in humans.
Maher S; Geoghegan C; Brayden DJ
Expert Opin Drug Deliv; 2021 Feb; 18(2):273-300. PubMed ID: 32937089
[TBL] [Abstract][Full Text] [Related]
15. Formulation strategies to improve the efficacy of intestinal permeation enhancers
Maher S; Brayden DJ
Adv Drug Deliv Rev; 2021 Oct; 177():113925. PubMed ID: 34418495
[TBL] [Abstract][Full Text] [Related]
16. Evaluation in pig of an intestinal administration device for oral peptide delivery.
Berg S; Uggla T; Antonsson M; Nunes SF; Englund M; Rosengren L; Fahraj M; Wu X; Govender R; Söderberg M; Janzén D; Van Zuydam N; Hugerth A; Larsson A; Abrahmsén-Alami S; Abrahamsson B; Davies N; Bergström CAS
J Control Release; 2023 Jan; 353():792-801. PubMed ID: 36493948
[TBL] [Abstract][Full Text] [Related]
17. A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms.
Tuvia S; Pelled D; Marom K; Salama P; Levin-Arama M; Karmeli I; Idelson GH; Landau I; Mamluk R
Pharm Res; 2014 Aug; 31(8):2010-21. PubMed ID: 24558008
[TBL] [Abstract][Full Text] [Related]
18. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
19. Men with acromegaly need higher doses of octreotide than women.
Edén Engström B; Burman P; Karlsson FA
Clin Endocrinol (Oxf); 2002 Jan; 56(1):73-7. PubMed ID: 11849249
[TBL] [Abstract][Full Text] [Related]
20. Progress in the formulation and delivery of somatostatin analogs for acromegaly.
Fattah S; Brayden DJ
Ther Deliv; 2017 Oct; 8(10):867-878. PubMed ID: 28944744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
